Recent Cardiology Updates for 2025–2026
Heart Failure: Expanded Therapeutic Arsenal
Finerenone (Kerendia) has received FDA approval for heart failure with left ventricular ejection fraction ≥40% (HFmrEF/HFpEF), representing a major therapeutic advance for this previously difficult-to-treat population 1, 2.
Guideline-Directed Medical Therapy for HFrEF Now Includes Four Drug Classes
The 2022 AHA/ACC/HFSA guidelines established a foundational four-pillar approach 3:
- SGLT2 inhibitors (Class 1 recommendation)
- ACE inhibitors/ARNi (sacubitril-valsartan)
- Beta blockers
- Mineralocorticoid receptor antagonists (MRAs)
All four classes should be initiated and optimized in patients with HFrEF unless contraindicated, as this combination has demonstrated the greatest mortality and morbidity reduction.
Heart Failure with Mildly Reduced/Preserved Ejection Fraction
For HFmrEF (LVEF 41-49%):
- SGLT2 inhibitors: Class 2a recommendation 3
- ARNi, ACEi, ARB, MRA, beta blockers: Class 2b (weaker evidence)
For HFpEF (LVEF ≥50%):
- SGLT2 inhibitors: Class 2a recommendation 3
- MRAs and ARNi: Class 2b recommendations 3
- Finerenone specifically approved for LVEF ≥40% in 2025 1
Critical pitfall: Patients with "improved LVEF" (previously HFrEF, now LVEF >40%) must continue their full HFrEF regimen—do not discontinue therapies when ejection fraction improves 3.
Acute Coronary Syndromes: Simplified Antiplatelet Strategies
Dual Antiplatelet Therapy Duration
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS guidelines challenge the traditional one-year DAPT paradigm 4, 5:
For ACS patients undergoing PCI:
- Loading dose of aspirin + P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) is Class 1 4
- Shorter DAPT durations (3-6 months) are now supported by recent trials (TARGET FIRST, MASTER DAPT) 5
- Consider patient-specific thrombotic vs. bleeding risk when determining duration
For patients with atrial fibrillation requiring anticoagulation after PCI:
- Discontinue aspirin after 1-4 weeks while maintaining P2Y12 inhibitor + anticoagulant (Class 2a) 6
- Earlier aspirin discontinuation (<1 week) is acceptable when P2Y12 inhibitor + therapeutic anticoagulation achieved 6
- Default to dual therapy (P2Y12 + DOAC) from outset rather than triple therapy for most patients 6
Hypertrophic Cardiomyopathy: First-in-Class Therapy
The 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR HCM guidelines introduced major changes in medical management 7:
Obstructive HCM Treatment Algorithm
For symptomatic obstructive HCM:
- First-line: Beta blockers or non-dihydropyridine calcium channel blockers
- Persistent symptoms: Add disopyramide OR consider septal reduction therapy (SRT) at experienced centers (Class 1) 7
- Novel option: First-in-class cardiac myosin inhibitors now available for obstructive HCM 8
Sudden Cardiac Death Risk Stratification
Key update: Risk assessment and ICD decision-making now applies to all ages (previously ≥16 years) 7:
- Use validated 5-year sudden death risk calculators
- Discuss estimated mortality rates during shared decision-making
- Consider ICD for patients with ≥1 major SCD risk factor
Pediatric-Specific Recommendations
Exercise stress testing is now Class 1 for ALL pediatric HCM patients (symptomatic or asymptomatic) to determine functional capacity and provide prognostic information 7.
Chronic Coronary Syndromes: Paradigm Shift in Diagnosis and Management
INOCA/ANOCA Recognition
The 2024 ESC CCS guidelines fundamentally reshape the approach to angina beyond obstructive CAD 9, 10:
Invasive coronary function testing (CFT) should guide mechanism-based therapy (Class 2a) 9:
For coronary microvascular dysfunction (CMD):
- Beta blockers (Class 2a)
- Calcium channel blockers
- Ranolazine, trimetazidine, ivabradine
- ACE inhibitors for endothelial dysfunction (Class 2a) 9
For vasospastic angina:
- Calcium channel blockers (Class 1) 9
- May require unusually high doses (diltiazem 400-960 mg/day)
- Nitrates (Class 2a)
- Combination therapy often necessary
Initial Diagnostic Testing Strategy
The 2024 ESC guidelines provide a stepwise algorithm 10:
- Estimate clinical likelihood of obstructive CAD
- Adjust based on risk factors and biomarkers
- Choose appropriate first-line test (anatomical vs. functional)
- Sequential testing to rule in/out functionally significant disease
Cardiac Arrest and Post-Resuscitation Care
Temperature Management
The 2025 AHA guidelines updated post-cardiac arrest temperature control 11:
- Target normothermia (36-37.5°C) for at least 24 hours
- Avoid hyperthermia (>37.5°C)
- Routine hypothermia (<36°C) no longer recommended for most patients
Oxygenation and Ventilation Targets
Immediate post-ROSC management 11:
- Initial 100% FiO2 until reliable SpO2 measurement
- Target SpO2 90-98% (PaO2 60-105 mmHg)
- Target PaCO2 35-45 mmHg (unless severe acidemia present)
- Mean arterial pressure ≥65 mmHg
Coronary Angiography
Early coronary angiography remains indicated for post-cardiac arrest patients with suspected cardiac etiology, particularly with STEMI or high suspicion for ACS 11.
Preventive Cardiology: Label Expansions
Bempedoic Acid
Label expansion in 2024-2025 for additional cardiovascular risk reduction 8:
- Non-statin LDL-lowering agent
- Particularly useful in statin-intolerant patients
- Demonstrated cardiovascular outcomes benefit
Semaglutide (GLP-1 Receptor Agonist)
Expanded cardiovascular indications 8:
- Beyond diabetes management
- Cardiovascular risk reduction in obesity
- The 2024 ESC CCS guidelines include recommendations for SGLT-2 inhibitors and/or GLP-1 receptor agonists in CCS patients (Class recommendation varies by indication) 10
Resistant Hypertension
First-in-class agents approved for resistant hypertension in 2024 8:
- Represents breakthrough for patients failing conventional triple therapy
- Specific agents and mechanisms detailed in specialized hypertension literature
Pulmonary Arterial Hypertension
New first-in-class therapy approved in 2024 8 for PAH management, expanding options beyond traditional prostacyclin, endothelin receptor antagonist, and phosphodiesterase-5 inhibitor pathways.
Key Practical Considerations
Antiplatelet Therapy Simplification
The trend across 2025-2026 guidelines favors shorter, simpler regimens 5, 12:
- Shorter DAPT after ACS/PCI when bleeding risk elevated
- Earlier transition from triple to dual therapy in AF patients
- Patient-tailored approaches based on anatomy and shared decision-making
Earlier Intervention Philosophy
The 2025 ESC valvular guidelines (referenced in interventional updates) promote earlier intervention 12:
- Even in selected asymptomatic patients
- Predominance of percutaneous approaches when anatomy suitable
- Shared decision-making with patient preference central
Device Therapies
Emerging device options in 2025 2:
- preCARDIA system for heart failure
- CRT-D optimization strategies
- Coronary sinus reducer therapy (requires further study per ESC guidelines) 9
Critical Gaps and Ongoing Research
Major trials initiated or ongoing in 2025 2:
- DAPA ACT HF-TIMI 68 (completed, informing SGLT2i use)
- VICTOR trial (completed)
- Stem cell therapy trials showing promise
- Novel mechanical circulatory support strategies
Unmet needs highlighted across guidelines 3, 9:
- Optimal antithrombotic therapy in INOCA/ANOCA uncertain
- Targeted medical therapy for microvascular disease remains largely empirical
- Myocardial bridging diagnosis and treatment lack evidence
- Neuromodulation and therapeutic angiogenesis require further study